drugset / Trial / NCT01471730

The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery

NCT01471730

Phase 3 Completed 119 enrolled IRCCS Policlinico S. Donato CSL Behring · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Prospective, randomized, double blind trial. The rationale of the study is the concept that fresh frozen plasma (FFP) is still largely used in cardiac surgery, despite the fact that prothrombin complexes and fibrinogen are available.The experimental hypothesis is that cardiac surgery patients may be operated with no use of FFP and with a coagulation factors replacement based on fibrinogen and prothrombin complexes (when needed). Primary endpoint: Transfusion avoidance Secondary endpoints: Transfusion limitation, massive blood transfusion, bleeding. Study population: high-risk adult cardiac surgery patients Sample size : 2 groups of 60 patients each

Timeline

Start
2011-11
Primary completion
2014-12
Completion
2014-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fibrinogen Concentrate Human Protein / enzyme biologic
Comparator Prothrombin complex Protein / enzyme biologic 7 iu/kg

Indications